The fundamental immunosuppressive interactions within the TME are discussed and subsequently it is examined how these agents enhance immune responses by reprogramming stromal and immune cells, as well as their secreted mediators within the TIME.
Abstract
The immunosuppressive stroma in colorectal cancer (CRC) plays a central role in therapeutic resistance. Modulating key targets within this stromal compartment has been proposed as a promising strategy for restoring antitumor immunity and overcoming resistance mechanisms. Several immunomodulatory agents, including next-generation immunotherapies, small-molecule inhibitors targeting specific receptors or signaling pathways, and natural compounds, have shown potential for remodeling the tumor immune microenvironment (TIME). In addition, nanoparticle-based delivery systems may further enhance the therapeutic efficacy of these agents. Evidence from both preclinical and clinical studies suggests that targeting stromal and immunosuppressive cells can effectively remodel the antitumor immune response in CRC. Furthermore, specific inhibitors, natural products, and their nanoformulations may enhance antitumor immunity by suppressing the recruitment and activity of immunosuppressive stromal and immune cells. This review summarizes the current knowledge of emerging pharmacological agents, including immunomodulators, therapeutic drugs, and their nanoformulations, for restoring antitumor immunity in CRC. It first discusses the fundamental immunosuppressive interactions within the TME and subsequently examines how these agents enhance immune responses by reprogramming stromal and immune cells, as well as their secreted mediators within the TIME.
The tumor microenvironment (TME) plays a major role in cancer progression, immune evasion, and resistance to immunotherapy. Coumarins, a structurally diverse class of natural and synthetic compounds, have attracted increasing attention because of their anticancer, anti-inflammatory, antioxidant, and immunomodulatory pr...
The development and drug resistance of breast cancer are closely associated with the heterogeneity of the tumor microenvironment (TME). Immunosuppressive cells, activated matrix components, abnormal vascular networks, and metabolic reprogramming within the TME collectively create a niche that promotes tumor survival. D...
Yan-Cai Liu, Yan-Ran Yang, Jiang-Long Wang et al.· Natural Products and Biopros...· 0 citations
With advances in deciphering the intricate interplay between tumors and the immune system, tumor immunotherapy has flourished significantly and has revolutionized conventional tumor therapies, owing to its durable immunological memory and favorable safety profile. Nevertheless, immunotherapy is not currently beneficial...
Pengfei Su, Ying-Jing Zhang, T. Yu et al.· International Immunopharmaco...· 0 citations
This review provides an integrated and conceptual analysis of the HCC immune landscape, delineating the mechanistic drivers underlying immune suppression, summarizes current immune-based classification frameworks, and dissects the context-dependent functions of key immune cell populations in tumor progression.
Jia-Qian Zhang, Si-Wen Li, Xiang-Long Ma et al.· Cancer Biology and Medicine· 1 citation
Current therapeutic strategies targeting TAMs are reviewed, including approaches directed against macrophage-associated receptors, signaling pathways, and epigenetic and metabolic regulators and emerging TAM-targeted therapeutic modalities are discussed, highlighting their potential to enhance antitumor immunity and im...
Shweta S. Joshi, Judith A. Varner· Trends in Cancer· 0 citations
Future studies must aim to design nanoparticles that maximize tumor uptake, incorporate predictive biomarkers, and optimize clinical utility and therapeutic efficacy to enhance translational success.
A. Singh, Shatrudhan Prajapati, Shikha Yadav et al.· Current Pharmacogenomics and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.